Cargando…
Immune-related adverse events in cancer patients treated with immune checkpoint inhibitors: A single-center experience
Immune checkpoint inhibitors (ICIs) like cytotoxic T-lymphocyte-associated protein 4 (anti-CTLA4) and programmed death cell protein 1 (anti-PD1) have revolutionized cancer treatment. As ICI use becomes widespread, more immune-related adverse events (irAE's) are being reported. Our aim was to in...
Autores principales: | Kaur, Aneet, Doberstein, Taylor, Amberker, Rachana Ramesh, Garje, Rohan, Field, Elizabeth Hirak, Singh, Namrata |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Wolters Kluwer Health
2019
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6799752/ https://www.ncbi.nlm.nih.gov/pubmed/31593084 http://dx.doi.org/10.1097/MD.0000000000017348 |
Ejemplares similares
-
Immune checkpoint inhibitor-induced refractory polyarthritis rapidly improved by sarilumab and monitoring with joint ultrasonography: A case report
por: Abe, Kazuya, et al.
Publicado: (2022) -
Clinical and laboratory features of patients with focal lymphocytic sialadenitis on minor salivary gland biopsy for sicca symptoms: A single-center experience
por: Ayesha, Bibi, et al.
Publicado: (2021) -
Catastrophic antiphospholipid syndrome in lupus-associated immune thrombocytopenia treated with eltrombopag A case series and literature review
por: Garra, Wakar, et al.
Publicado: (2023) -
The association between age and adverse events due to biologic disease-modifying antirheumatic drugs in patients with rheumatoid arthritis: A retrospective cohort study
por: Ikari, Yuzo, et al.
Publicado: (2020) -
Identifying the hub genes and immune infiltration related to pyroptosis in rheumatoid arthritis
por: Xie, Wei, et al.
Publicado: (2021)